PRT12396 (mutant-selective JAK2V617F inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- February 3 — Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor: FDA cleared IND for PRT12396 (Prelude Therapeutics), a first-in-class mutant-selective JAK2V617F inhibitor binding the JH2 pseudokinase deep pocket; Phase 1 dosing in MPN patients anticipated by Q2 2026 (regulatory/pipeline announcement, no clinical efficacy or safety data yet). (novelty: 4)
Open questions
Related
Contributing findings
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
February 3, 2026
novelty 4
per-area 4
introduces